Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis

Endocrinology

Volumn 149, Issue 3, 2008, Pages 1302-1313

  Perrini, Sebastio ^a   Natalicchio, Annalisa ^a   Laviola, Luigi ^a   Cignarelli, Angelo ^a   Melchiorre, Mariangela ^a   De Stefano, Francesca ^a   Caccioppoli, Cristina ^a   Leonardini, Anna ^a   Martemucci, Sabina ^a   Belsanti, Gaetana ^a   Miccoli, Sara ^a   Ciampolillo, Anna ^a   Corrado, Ada ^b   Cantatore, Francesco Paolo ^b   Giorgino, Riccardo ^a   Giorgino, Francesco ^a,c  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; GLYCOGEN SYNTHASE KINASE 3; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ARTICLE; CELL POPULATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MALE; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OSTEOBLASTS; OSTEOPOROSIS; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 40849120759     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-1349     Document Type: Article

References (54)

1. Ohlsson C, Bengtsson B, Isaksson O, Andreassen TT, Slootweg MC 1998 Growth hormone and bone. Endocr Rev 19:55-79
2. Baron R 1996 Molecular mechanisms of bone resorption: therapeutic implications. Rev Rhum Engl Ed 63:633-638
3. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ 1999 Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357
4. Karsenty G, Wagner EF 2002 Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2:389-406
5. Kasuga M, Karlsson FA, Kahn CR 1982 Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. Science 215:185-187
6. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J, Fujita-Yamaguchi Y 1986 Insulin-like growth factor-I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5:2503-2512
7. Kadowaki T, Tobe K, Honda-Yamamoto R, Tamemoto H, Kaburagi Y, Momomura K, Ueki K, Takahashi Y, Yamauchi T, Akanuma Y, Yazaki Y 1996 Signal transduction mechanism of insulin and insulin-like growth factor-1. Endocr J 43:33-34
8. Yamaguchi M, Ogata N, Shinoda Y, Akune T, Kamekura S, Terauchi Y, Kadowaki T, Hoshi K, Chung UI, Nakamura K, Kawaguchi H 2005 Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology 146:2620-2628
9. Huang C, Thirone AC, Huang X, Klip A 2005 Differential contribution of insulin receptor substrates 1 versus 2 to insulin signaling and glucose uptake in L6 myotubes. J Biol Chem 280:19426-19435
10. Akune T, Ogata N, Hoshi K, Kubota N, Terauchi Y, Tobe K, Takagi H, Azuma Y, Kadowaki T, Nakamura K, Kawaguchi H 2002 Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol 159:147-156
11. Ogata N, Chikazu D, Kubota N, Terauchi Y, Tobe K, Azuma Y, Ohta T, Kadowaki T, Nakamura K, Kawaguchi H 2000 Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest 105:935-943
12. Yamauchi T, Tobe K, Tamemoto H, Ueki K, Kaburagi Y, Yamamoto-Honda R, Takahashi Y, Yoshizawa F, Aizawa S, Akanuma Y, Sonenberg N, Yazaki Y, Kadowaki T 1996 Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol 16:3074-3084
13. Cheatham B, Kahn CR 1995 Insulin action and the insulin signaling network. Endocr Rev 16:117-142
14. Entingh-Pearsall A, Kahn CR 2004 Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. J Biol Chem 279:38016-38024
15. Zhang W, Lee JC, Kumar S, Gowen M 1999 ERK pathway mediates the activation of Cdk2 in IGF-1-induced proliferation of human osteosarcoma MG-63 cells. J Bone Miner Res 14:528-535
16. Grey A, Chen Q, Xu X, Callon K, Cornish J 2003 Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology 144:4886-4893
17. Kiepe D, Ciarmatori S, Hoeflich A, Wolf E, Tonshoff B 2005 Insulin-like growth factor (IGF)-I stimulates cell proliferation and induces IGF binding protein (IGFBP)-3 and IGFBP-5 gene expression in cultured growth plate chondrocytes via distinct signaling pathways. Endocrinology 146:3096-3104
18. Krakauer JC, McKenna MJ, Rao DS, Whitehouse FW 1997 Bone mineral density in diabetes. Diabetes Care 20:1339-1340
19. Laron Z 1999 The essential role of IGF-I: lessons from the long-term study and treatment of children and adults with Laron syndrome. J Clin Endocrinol Metab 84:4397-4404
20. Nicolas V, Prewett A, Bettica P, Mohan S, Finkelman RD, Baylink DJ, Farley JR 1994 Age-related decreases in insulin-like growth factor-I and transforming growth factor-β in femoral cortical bone from both men and women: implications for bone loss with aging. J Clin Endocrinol Metab 78:1011-1016
21. Rosen CJ 2004 Insulin-like growth factor I and bone mineral density: experience from animal models and human observational studies. Best Pract Res Clin Endocrinol Metab 18:423-435
22. Canalis E 1997 Insulin-like growth factors and osteoporosis. Bone 21:215-216
23. Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A 1996 Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab 81:3864-3870
24. Ghiron LJ, Thompson JL, Holloway L, Hintz RL, Butterfield GE, Hoffman AR, Marcus R 1995 Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res 10:1844-1852
25. Cadarette SM, Jaglal SB, Kreiger N, McIsaac WJ, Darlington GA, Tu JV 2000 Development and validation of the osteoporosis risk assessment instrument to facilitate selection of women for bone densitometry. CMAJ 162:1289-1294
26. Corrado A, Cantatore FP, Grano M, Colucci S 2005 Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clin Rheumatol 24:527-534
27. Mogi M, Togari A 2003 Activation of caspases is required for osteoblastic differentiation. J Biol Chem 278:47477-47482
28. Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K 2002 Activations of ERK1/2 and JNK by transforming growth factor β negatively regulate Smad3-induced alkaline phosphatase activity and mineralization in mouse osteoblastic cells. J Biol Chem 277:36024-36031
29. Perrini S, Natalicchio A, Laviola L, Belsanti G, Montrone C, Cignarelli A, Minielli V, Grano M, De Pergola G, Giorgino R, Giorgino F 2004 Dehydroepiandrosterone stimulates glucose uptake in human and murine adipocytes by inducing GLUT1 and GLUT4 translocation to the plasma membrane. Diabetes 53:41-52
30. Natalicchio A, Laviola L, De Tullio C, Renna LA, Montrone C, Perrini S, Valenti G, Procino G, Svelto M, Giorgino F 2004 Role of the p66Shc isoform in insulin-like growth factor I receptor signaling through MEK/Erk and regulation of actin cytoskeleton in rat myoblasts. J Biol Chem 279:43900-43909
31. Alessi DR, Cohen P 1998 Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8:55-62
32. Marie PJ, Lomri A, de Vernejoul MC, Morieux C, Graulet AM, Guéris J, Llach F 1989 Relationships between histomorphometric features of bone formation and bone cell characteristics in vitro in renal osteodystrophy. J Clin Endocrinol Metab 1989 69:1166-1173
33. Clemmons DR, Maile LA 2005 Interaction between insulin-like growth factor-I receptor and αVβ3 integrin linked signaling pathways: cellular responses to changes in multiple signaling inputs. Mol Endocrinol 19:1-11
34. Ling Y, Maile LA, Clemmons DR 2003 Tyrosine phosphorylation of the β3-subunit of the αVβ3 integrin is required for membrane association of the tyrosine phosphatase SHP-2 and its further recruitment to the insulin-like growth factor I receptor. Mol Endocrinol 17:1824-1833
35. Ling Y, Maile LA, Badley-Clarke J, Clemmons DR 2005 DOK1 mediates SHP-2 binding to the αVβ3 integrin and thereby regulates insulin-like growth factor I signaling in cultured vascular smooth muscle cells. J Biol Chem 280:3151-3158
36. Maile LA, Clemmons DR 2002 Regulation of insulin-like growth factor I receptor dephosphorylation by SHPS-1 and the tyrosine phosphatase SHP-2. J Biol Chem 277:8955-8960
37. Maile L, Clemmons DR 2002 The αVβ3 integrin regulates insulin-like growth factor I (IGF-I) receptor phosphorylation by altering the rate of recruitment of the Src-homology 2-containing phosphotyrosine phosphatase-2 to the activated IGF-I receptor. Endocrinology 143:4259-4264
38. Teitelbaum SL 2005 Osteoporosis and integrins. J Clin Endocrinol Metab 90:2466-2468
39. Yamamoto M, Fisher JE, Gentile M, Seedor JG, Leu CT, Rodan SB, Rodan GA 1998 The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology 139:1411-1419
40. He W, Craparo A, Zhu Y, O'Neill TJ, Wang LM, Pierce JH, Gustafson TA 1996 Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors. Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2. J Biol Chem 271:11641-11645
41. Sawka-Verhelle D, Tartare-Deckert S, White MF, Van Obberghen E 1996 Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain comprising amino acids 591-786. J Biol Chem 271:5980-5983
42. Leahy M, Lyons A, Krause D, O'Connor R 2004 Impaired Shc, Ras, and MAPK activation but normal Akt activation in FL5.12 cells expressing an insulin-like growth factor I receptor mutated at tyrosines 1250 and 1251. J Biol Chem 279:18306-18313
43. Miele C, Caruso M, Calleja V, Auricchio R, Oriente F, Formisano P, Condorelli G, Cafieri A, Sawka-Verhelle D, Van Obberghen E, Beguinot F 1999 Differential role of insulin receptor substrate (IRS)-1 and IRS-2 in L6 skeletal muscle cells expressing the Arg1152 3 Gln insulin receptor. J Biol Chem 274:3094-3102
44. Inoue G, Cheatham B, Emkey R, Kahn CR 1998 Dynamics of insulin signaling in 3T3-L1 adipocytes. Differential compartmentalization and trafficking of insulin receptor substrate (IRS)-1 and IRS-2. J Biol Chem 273:11548-11555
45. Giorgino F, Logoluso F, Davalli AM, Napoli R, Laviola L, Hirshman MF, Horton ES, Weir GC, Smith RJ 1999 Islet transplantation restores normal levels of insulin receptor and substrate tyrosine phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle and myocardium of streptozocin-induced diabetic rats. Diabetes 48:801-812
46. Laviola L, Belsanti G, Davalli AM, Napoli R, Perrini S, Weir GC, Giorgino R, Giorgino F 2001 Effects of streptozocin diabetes and diabetes treatment by islet transplantation on in vivo insulin signaling in rat heart. Diabetes 50:2709-2720
47. Laviola L, Perrini S, Belsanti G, Natalicchio A, Montrone C, Leonardini A, Vimercati A, Scioscia M, Selvaggi L, Giorgino R, Greco P, Giorgino F 2005 Intrauterine growth restriction in humans is associated with abnormalities in placental insulin-like growth factor signaling. Endocrinology 146:1498-1505
48. Shimoaka T, Kamekura S, Chikuda H, Hoshi K, Chung UI, Akune T, Maruyama Z, Komori T, Matsumoto M, Ogawa W, Terauchi Y, Kadowaki T, Nakamura K, Kawaguchi H 2004 Impairment of bone healing by insulin receptor substrate-1 deficiency. J Biol Chem 279:15314-15322
49. Rodriguez JP, Rios S, Fernandez M, Santibanez JF 2004 Differential activation of ERK1,2 MAP kinase signaling pathway in mesenchymal stem cell from control and osteoporotic postmenopausal women. J Cell Biochem 92:745-754
50. Rescan C, Coutant A, Talarmin H, Theret N, Glaise D, Guguen-Guillouzo C, Baffet G 2001 Mechanism in the sequential control of cell morphology and S phase entry by epidermal growth factor involves distinct MEK/ERK activations. Mol Biol Cell 12:725-738
51. Marie PJ, de Vernejoul MC, Connes D, Hott M 1991 Decreased DNA synthesis by cultured osteoblastic cells in eugonadal osteoporotic men with defective bone formation. J Clin Invest 88:1167-1172
52. Jung F, Haendeler J, Goebel C, Zeiher AM, Dimmeler S 2000 Growth factor-induced phosphoinositide 3-OH kinase/Akt phosphorylation in smooth muscle cells: induction of cell proliferation and inhibition of cell death. Cardiovasc Res 48:148-157
53. Vanhaesebroeck B, Alessi DR 2000 The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346:561-576
54. Cheng MZ, Rawlinson SC, Pitsillides AA, Zaman G, Mohan S, Baylink DJ, Lanyon LE 2002 Human osteoblasts' proliferative responses to strain and 17β-estradiol are mediated by the estrogen receptor and the receptor for insulin-like growth factor I. J Bone Miner Res 17:593-602